• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Globus Medical Schedules First Quarter Earnings Release and Conference Call

    4/17/25 4:30:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email

    AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.

    Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcasts.

    To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

    The audio archive will be available after the call on the Investors page of the Globus Medical website.

    About Globus Medical, Inc.

    Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

    Safe Harbor Statements

    All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the Nevro business, trends in the medical industry and the ability of Globus Medical and Nevro to: (i) successfully integrate and achieve anticipated synergies, (ii) manage our growth, (iii) sustain profitability, (iv) sustain demand for products, (v) compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and the ability to attract and retain sales and other personnel), (vi) rapidly develop and introduce new products, (vii) develop and execute successful business strategies, (viii) comply with changes and applicable laws and regulations that are or may become applicable to Globus Medical and/or Nevro, (ix) safeguard our intellectual property, and (x) succeed in defending against legal proceedings in addition to general economic conditions and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of each of Globus Medical and Nevro contained in each company's most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in each company's Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, both Globus Medical and Nevro operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for Globus Medical and Nevro to predict all risk factors and uncertainties, nor can we assess the impact of all factors on the Globus Medical business and Nevro business, respectively, or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Globus Medical and Nevro undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

    Contacts:

    Investors:

    Brian Kearns

    Senior Vice President, Corporate Development and Investor Relations

    (610) 930-1800

    [email protected]

    www.globusmedical.com

    Media:

    Moran Chavez

    Senior Director, Corporate Affairs

    (619) 318-7681

    [email protected]



    Primary Logo

    Get the next $GMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    5/27/2025Buy → Neutral
    BTIG Research
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    10/20/2023$75.00Buy
    ROTH MKM
    9/19/2023$61.00Hold → Buy
    Stifel
    More analyst ratings

    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Globus Medical Announces $500 Million Share Repurchase Program

      AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. "We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation," said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. "Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforc

      5/15/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Davidar David D

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:18:17 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Deford John A

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:15:42 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Douglas Robert Andrew

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:13:33 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Globus Medical downgraded by BTIG Research

      BTIG Research downgraded Globus Medical from Buy to Neutral

      5/27/25 9:07:37 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00

      1/10/25 8:55:48 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously

      12/2/24 6:57:12 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care